Leukocyte apheresis is a medical device therapy (selective granulocyte/monocyte adsorptive {GMA} apheresis; GMDN[1] code: 47306) for the treatment of inflammation of the colon. It works by removing from the blood a group of white blood cells called activated leukocytes[2] that play a key role in the inflammatory stages of ulcerative colitis (UC).[3] Selectively reducing these cells in the blood helps to reduce inflammation in the colon.[4] Leukocyte apheresis can help UC patients with chronic, grumbling disease who are either unsuitable for, intolerant of, or failing on medicines described above.[5]
| Leukocyte apheresis | |
|---|---|
| Specialty | Gastrointestinal |
References
edit- ^ "Global Medical Device Network". Archived from the original on 2014-08-15.
- ^ Hanai H.; et al. (January 2011). "The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review". Clinical & Experimental Immunology. 163 (1): 50–58. doi:10.1111/j.1365-2249.2010.04279.x. PMC 3010911. PMID 21078086.50-58&rft.date=2011-01&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010911#id-name=PMC&rft_id=info:pmid/21078086&rft_id=info:doi/10.1111/j.1365-2249.2010.04279.x&rft.au=Hanai H.&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010911&rfr_id=info:sid/en.wikipedia.org:Leukocyte apheresis" class="Z3988">
- ^ Nikolaus S., Schreiber S.; et al. (April 1998). "Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation". Gut. 42 (4): 470–476. doi:10.1136/gut.42.4.470. PMC 1727082. PMID 9616306.470-476&rft.date=1998-04&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1727082#id-name=PMC&rft_id=info:pmid/9616306&rft_id=info:doi/10.1136/gut.42.4.470&rft.au=Nikolaus S., Schreiber S.&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1727082&rfr_id=info:sid/en.wikipedia.org:Leukocyte apheresis" class="Z3988">
- ^ Muratov V.; et al. (2008). "Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis". Journal of Gastroenterology. 43 (4): 277–282. doi:10.1007/s00535-007-2156-3. PMID 18458843. S2CID 23733856.277-282&rft.date=2008&rft_id=https://api.semanticscholar.org/CorpusID:23733856#id-name=S2CID&rft_id=info:pmid/18458843&rft_id=info:doi/10.1007/s00535-007-2156-3&rft.au=Muratov V.&rfr_id=info:sid/en.wikipedia.org:Leukocyte apheresis" class="Z3988">
- ^ Dignass A.; et al. (2015). "P511 Efficacy and safety of granulocyte/monocyte adsorptive apheresis in steroid-dependent Active Ulcerative Colitis with insufficient response or intolerance to immunosuppressants and/or biological therapies (the ART trial): Results at 24 and 48 weeks". ecco-ibd.eu. The European Crohn's and Colitis Organisation (ECCO).
